We have previously reported the clinical and immunological effects of vaccination with dendritic cells electroporated with WT1 mRNA (WT1/DC) in 10 patients with acute myeloid leukemia (AML) (Van Tendeloo et al. PNAS 2010). In the present study, we expanded on the initial results and investigated WT1/DC as an adjuvant treatment in 60 high-risk cancer patients.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Cytotherapy
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect